Andrew M Wilson1,2, Allan B Clark1, Tony Cahn3, Edwin R Chilvers4, William Fraser1,5, Matthew Hammond6, David M Livermore1, Toby M Maher5,7,8, Helen Parfrey9, Ann Marie Swart6, Susan Stirling6, David R Thickett10, Moira Whyte11. 1. Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, Norfolk, United Kingdom. 2. Department of Respiratory Medicine, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, Norfolk, United Kingdom. 3. Department of Respiratory Medicine, Bedford Hospitals NHS Trust, South Wing, Bedford, United Kingdom. 4. National Heart and Lung Institute, Imperial College London, London, United Kingdom. 5. Department of Endocrinology and Clinical Biochemistry, Norfolk and Norwich University Hospital NHS Foundation Trust, Colney Lane, Norwich, Norfolk, United Kingdom. 6. Norwich Clinical Trials Unit, University of East Anglia, Norwich Research Park, Norwich, Norfolk, United Kingdom. 7. Hastings Centre for Pulmonary Research and Division of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles. 8. NIHR Respiratory Clinical Research Facility, Royal Brompton Hospital, London, United Kingdom. 9. Royal Papworth Hospital NHS Foundation Trust, Papworth Road, Cambridge Biomedical Campus, Cambridge, United Kingdom. 10. Institute of Inflammation and Aging, University of Birmingham, Edgbaston, Birmingham, United Kingdom. 11. MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom.
Abstract
Importance: Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limited treatment options. Patients with IPF have altered lung microbiota, with bacterial burden within the lungs associated with mortality; previous studies have suggested benefit with co-trimoxazole (trimethoprim-sulfamethoxazole). Objective: To determine the efficacy of co-trimoxazole in patients with moderate and severe IPF. Design, Setting, and Participants: Double-blind, placebo-controlled, parallel randomized trial of 342 patients with IPF, breathlessness (Medical Research Council dyspnea scale score >1), and impaired lung function (forced vital capacity ≤75% predicted) conducted in 39 UK specialist interstitial lung disease centers between April 2015 (first patient visit) and April 2019 (last patient follow-up). Interventions: Study participants were randomized to receive 960 mg of oral co-trimoxazole twice daily (n = 170) or matched placebo (n = 172) for between 12 and 42 months. All patients received 5 mg of folic acid orally once daily. Main Outcomes and Measures: The primary outcome was time to death (all causes), lung transplant, or first nonelective hospital admission. There were 15 secondary outcomes, including the individual components of the primary end point respiratory-related events, lung function (forced vital capacity and gas transfer), and patient-reported outcomes (Medical Research Council dyspnea scale, 5-level EuroQol 5-dimension questionnaire, cough severity, Leicester Cough Questionnaire, and King's Brief Interstitial Lung Disease questionnaire scores). Results: Among 342 individuals who were randomized (mean age, 71.3 years; 46 [13%] women), 283 (83%) completed the trial. The median (interquartile range) duration of follow-up was 1.02 (0.35-1.73) years. Events per person-year of follow-up among participants randomized to the co-trimoxazole and placebo groups were 0.45 (84/186) and 0.38 (80/209), respectively, with a hazard ratio of 1.2 ([95% CI, 0.9-1.6]; P = .32). There were no statistically significant differences in other event outcomes, lung function, or patient-reported outcomes. Patients in the co-trimoxazole group had 696 adverse events (nausea [n = 89], diarrhea [n = 52], vomiting [n = 28], and rash [n = 31]) and patients in the placebo group had 640 adverse events (nausea [n = 67], diarrhea [n = 84], vomiting [n = 20], and rash [n = 20]). Conclusions and Relevance: Among patients with moderate or severe IPF, treatment with oral co-trimoxazole did not reduce a composite outcome of time to death, transplant, or nonelective hospitalization compared with placebo. Trial Registration: ISRCTN Identifier: ISRCTN17464641.
RCT Entities:
Importance: Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limited treatment options. Patients with IPF have altered lung microbiota, with bacterial burden within the lungs associated with mortality; previous studies have suggested benefit with co-trimoxazole (trimethoprim-sulfamethoxazole). Objective: To determine the efficacy of co-trimoxazole in patients with moderate and severe IPF. Design, Setting, and Participants: Double-blind, placebo-controlled, parallel randomized trial of 342 patients with IPF, breathlessness (Medical Research Council dyspnea scale score >1), and impaired lung function (forced vital capacity ≤75% predicted) conducted in 39 UK specialist interstitial lung disease centers between April 2015 (first patient visit) and April 2019 (last patient follow-up). Interventions: Study participants were randomized to receive 960 mg of oral co-trimoxazole twice daily (n = 170) or matched placebo (n = 172) for between 12 and 42 months. All patients received 5 mg of folic acid orally once daily. Main Outcomes and Measures: The primary outcome was time to death (all causes), lung transplant, or first nonelective hospital admission. There were 15 secondary outcomes, including the individual components of the primary end point respiratory-related events, lung function (forced vital capacity and gas transfer), and patient-reported outcomes (Medical Research Council dyspnea scale, 5-level EuroQol 5-dimension questionnaire, cough severity, Leicester Cough Questionnaire, and King's Brief Interstitial Lung Disease questionnaire scores). Results: Among 342 individuals who were randomized (mean age, 71.3 years; 46 [13%] women), 283 (83%) completed the trial. The median (interquartile range) duration of follow-up was 1.02 (0.35-1.73) years. Events per person-year of follow-up among participants randomized to the co-trimoxazole and placebo groups were 0.45 (84/186) and 0.38 (80/209), respectively, with a hazard ratio of 1.2 ([95% CI, 0.9-1.6]; P = .32). There were no statistically significant differences in other event outcomes, lung function, or patient-reported outcomes. Patients in the co-trimoxazole group had 696 adverse events (nausea [n = 89], diarrhea [n = 52], vomiting [n = 28], and rash [n = 31]) and patients in the placebo group had 640 adverse events (nausea [n = 67], diarrhea [n = 84], vomiting [n = 20], and rash [n = 20]). Conclusions and Relevance: Among patients with moderate or severe IPF, treatment with oral co-trimoxazole did not reduce a composite outcome of time to death, transplant, or nonelective hospitalization compared with placebo. Trial Registration: ISRCTN Identifier: ISRCTN17464641.
Authors: Harold R Collard; Christopher J Ryerson; Tamera J Corte; Gisli Jenkins; Yasuhiro Kondoh; David J Lederer; Joyce S Lee; Toby M Maher; Athol U Wells; Katerina M Antoniou; Juergen Behr; Kevin K Brown; Vincent Cottin; Kevin R Flaherty; Junya Fukuoka; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Martin Kolb; David A Lynch; Jeffrey L Myers; Ganesh Raghu; Luca Richeldi; Hiroyuki Taniguchi; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2016-08-01 Impact factor: 21.405
Authors: Mark Fisher; Steven D Nathan; Christian Hill; Jade Marshall; Fred Dejonckheere; Per-Olof Thuresson; Toby M Maher Journal: J Manag Care Spec Pharm Date: 2017-03
Authors: Matthew Hammond; Allan B Clark; Anthony P Cahn; Edwin R Chilvers; William Duncan Fraser; David M Livermore; Toby M Maher; Helen Parfrey; Ann Marie Swart; Susan Stirling; David Thickett; Moira Whyte; Andrew Wilson Journal: Trials Date: 2018-02-05 Impact factor: 2.279
Authors: Markus Hilty; Conor Burke; Helder Pedro; Paul Cardenas; Andy Bush; Cara Bossley; Jane Davies; Aaron Ervine; Len Poulter; Lior Pachter; Miriam F Moffatt; William O C Cookson Journal: PLoS One Date: 2010-01-05 Impact factor: 3.240
Authors: Christian Garzoni; Silvio D Brugger; Weihong Qi; Sarah Wasmer; Alexia Cusini; Philippe Dumont; Meri Gorgievski-Hrisoho; Kathrin Mühlemann; Christophe von Garnier; Markus Hilty Journal: Thorax Date: 2013-08-14 Impact factor: 9.139
Authors: Anna J Podolanczuk; Alyson W Wong; Shigeki Saito; Joseph A Lasky; Christopher J Ryerson; Oliver Eickelberg Journal: Am J Respir Crit Care Med Date: 2021-06-01 Impact factor: 21.405
Authors: Francesco Amati; Anna Stainer; Marco Mantero; Andrea Gramegna; Edoardo Simonetta; Giulia Suigo; Antonio Voza; Anoop M Nambiar; Umberto Cariboni; Justin Oldham; Philip L Molyneaux; Paolo Spagnolo; Francesco Blasi; Stefano Aliberti Journal: Int J Mol Sci Date: 2022-01-17 Impact factor: 5.923